Press Release Details

Organogenesis Holdings Inc. Reports Second Quarter and First Half 2019 Financial Results

August 9, 2019 at 7:00 AM EDT

CANTON, Mass., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for its second quarter ended June 30, 2019.

Second Quarter 2019 Financial Summary:

  • Net revenue of $64.9 million for the second quarter of 2019, up 49% compared to net revenue of $43.6 million for the second quarter of 2018. Net revenue comprised:
    • Net revenue from Advanced Wound Care products of $55.2 million, up 50% from the second quarter of 2018.
    • Net revenue from Surgical & Sports Medicine products of $9.7 million, up 46% from the second quarter of 2018.
  • Net revenue from the sale of PuraPly products of $29.7 million for the second quarter of 2019, up 133% from the second quarter of 2018.
  • Net revenue from the sale of non-PuraPly products of $35.3 million for the second quarter of 2019, up 14% from the second quarter of 2018.
  • Net loss was $9.6 million for the second quarter of 2019, compared to a net loss of $20.0 million for the second quarter of 2018.
  • Adjusted EBITDA loss of $4.8 million for the second quarter of 2019, compared to Adjusted EBITDA loss of $11.5 million for the second quarter of 2018.

Second Quarter 2019 and Recent Highlights:

  • On May 1, 2019, the Company announced that it received an Innovative Technology contract from Vizient, Inc. for its portfolio of Advanced Wound Care and Surgical & Sports Medicine products.
  • On July 1, 2019, the Company announced that the common stock of Organogenesis Holdings Inc. had been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes.

“We delivered another strong quarter of significant year-over-year revenue growth across both our Advanced Wound Care and Surgical and Sports Medicine portfolios,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “With continued successful execution against our commercial strategy, we grew our customer base and drove customer and clinician adoption deeper into existing accounts. We are pleased that our second quarter results reflected strong year-over-year growth across all products other than Affinity and also benefited from an increase in our amniotic capacity and an improvement in our ability to meet customer demand. Based on our strong commercial performance and our expectation that our amniotic capacity will increase again in the fourth quarter, we are updating our fiscal 2019 revenue guidance reflecting growth of 29% to 35% year-over-year. We are committed to delivering on our mission to provide integrated healing solutions that substantially improve medical outcomes while lowering the overall cost of care. We remain focused on commercial execution, operational progress – including the continued development of our new product pipeline – and improving our profitability profile.”

Net Revenue Summary:

The following table represents revenue by product grouping for the three and six months ended June 30, 2019:

  Three Months Ended
June 30,
  Increase/Decrease   Six Months Ended
June 30,
  Increase/Decrease 
(In thousands) 2019   2018   $ Change   % Change   2019
  2018
  $ Change
  % Change
Advanced Wound Care $ 55,211   $ 36,890   $ 18,321   50%   $ 103,055   $ 66,114   $ 36,941   56%
Surgical & Sports Medicine 9,737   6,662   3,075   46%   19,016   12,967   6,049   47%
Net revenue $ 64,948   $ 43,552   $ 21,396   49%   $ 122,071   $ 79,081   $ 42,990   54%
                                           

Second Quarter 2019 Results:

Net revenue for the second quarter of 2019 was $64.9 million, compared to $43.6 million for the second quarter of 2018, an increase of $21.4 million, or 49%. The increase in net revenue was driven by a $18.3 million increase in net revenue of Advanced Wound Care products and a $3.1 million increase in net revenue of Surgical & Sports Medicine products, representing growth of 50% and 46%, respectively, compared to the second quarter of 2018. The increase in Advanced Wound Care net revenue was primarily attributable to additional sales personnel, PuraPly regaining pass-through reimbursement status for the two-year period effective October 1, 2018 and the continued growth in adoption of our amniotic products. The increase in Surgical & Sports Medicine revenue was primarily due to the expansion of the sales force and penetration of existing and new customer accounts. Net revenue of PuraPly products for the second quarter of 2019 was $29.7 million, compared to $12.8 million for the second quarter of 2018, an increase of $16.9 million, or 133%. Net revenue of PuraPly products represented approximately 46% of net revenue in the second quarter of 2019, compared to 29% of net revenue in the second quarter of 2018.

Gross profit for the second quarter of 2019 was $45.5 million or 70% of net revenue, compared to $26.3 million, or 60% of net revenue for the second quarter of 2018, an increase of $19.2 million, or 73%. The improvement in gross profit and gross profit margin percentage resulted primarily from a more favorable product mix of revenue in the second quarter of 2019, PuraPly regaining pass-through reimbursement status, and volume-based manufacturing efficiencies.

Operating expenses for the second quarter of 2019 were $52.8 million, compared to $43.3 million for the second quarter of 2018, an increase of $9.5 million, or 22%. The increase in operating expenses in the second quarter of 2019 as compared to the second quarter of 2018 was driven primarily by higher selling, general and administrative expenses which increased to $49.0 million, compared to $37.7 million in the second quarter of 2018, an increase of $11.2 million, or 30%. The increase in selling, general and administrative expenses is primarily due to additional headcount, predominantly in the direct sales force, higher sales commissions and increased marketing and promotional expenses for the Company’s products. R&D expense was $3.9 million for the second quarter of 2019, compared to $2.0 million in the second quarter of 2018, an increase of $1.8 million, or 89%. The increase in R&D was driven by additional headcount and continued and new investment in clinical programs.

Operating loss for the second quarter of 2019 was $7.3 million, compared to an operating loss of $17.0 million for the second quarter of 2018, a decrease of $9.7 million, or 57%. Total other expenses, net, for the second quarter of 2019 were $2.3 million, compared to $3.0 million for the second quarter of 2018, a decrease of $0.7 million, or 22%. The decrease was driven primarily by a decrease in interest expense and decrease in the change in fair value of warrant liability.

Net loss for the second quarter of 2019 was $9.6 million, or $0.11 per share, compared to a net loss of $20.0 million, or $0.30 per share, for the second quarter of 2018, a decrease of $10.4 million, or 52%.

As of June 30, 2019, the Company had $20.0 million in cash and $90.2 million in debt obligations, of which $17.1 million were capital lease obligations, compared to $21.3 million in cash and $59.3 million in debt obligations, of which $17.7 million were capital lease obligations, as of December 31, 2018.

First Half 2019 Results:

Net revenue for the six months ended June 30, 2019 was $122.1 million, compared to $79.1 million for the first six months of 2018, an increase of $43.0 million, or 54%. The increase in net revenue was driven by a $36.9 million increase, or 56%, in net revenue of Advanced Wound Care products and a $6.0 million increase, or 47%, in net revenue of Surgical & Sports Medicine products compared to the prior year. Net revenue of PuraPly products for the six months ended June 30, 2019 were $55.1 million, compared to $23.4 million for the first six months of 2018, an increase of $31.8 million, or 136%. Net revenue of PuraPly products represented approximately 45% of net revenue for the six months ended June 30, 2019, compared to 30% for the first six months of 2018.

Gross profit for the six months ended June 30, 2019 was $85.6 million or 70% of net revenue, compared to $47.3 million, or 60% of net revenue, for the first six months of 2018, an increase of $38.4 million, or 81%. The largest contributors to the increase in gross margin from the year earlier period were increased sales volume due to the strength in our Advanced Wound Care products, PuraPly regaining pass-through reimbursement status for the 2-year period effective October 1, 2018, and incremental revenue from our Surgical & Sports Medicine products as a result of our NuTech Medical acquisition and the resulting higher margins realized as a result of manufacturing efficiencies associated with our Advanced Wound Care products.

Operating expenses for the six months ended June 30, 2019 were $105.1 million, compared to $84.3 million for the first six months of 2018, an increase of $20.8 million, or 25%. The increase in operating expenses in 2019 as compared to 2018 was driven primarily by higher selling, general and administrative expenses which increased to $97.9 million, compared to $75.9 million in 2018, an increase of $22.0 million, or 29%. The increase in selling, general and administrative expenses is primarily due to additional headcount, primarily in our direct sales force, higher legal, consulting fees and other costs associated with the ongoing operations of our business, and additional amortization associated with the intangible assets from the NuTech Medical acquisition attributable to the higher expected consumption of the related intangible assets’ economic benefits. Operating expenses for the six months ended June 30, 2019 were also impacted by higher R&D expense which was $7.2 million, compared to $4.9 million for the first six months of 2018, an increase of $2.4 million, or 49%.

Operating loss for the six months ended June 30, 2019 was $19.4 million, compared to an operating loss of $37.0 million for the first six months of 2018, a decrease of $17.6 million, or 47%. Total other expenses for the six months ended June 30, 2019 were $5.8 million, compared to $5.4 million for the first six months of 2018, an increase of $0.4 million, or 7%. The increase in total other expenses for the six months ended June 30, 2019 was driven primarily by a $1.9 million non-cash loss on the extinguishment of debt related to the write-off of unamortized debt discount upon repayment of the master lease agreement as well as early payment penalties in March 2019, offset partially by a decrease in interest expense of $1.2 million and decrease in the change in fair value of warrant liability of $0.2 million.

Net loss the six months ended June 30, 2019 was $25.3 million, or $0.28 per share, compared to a net loss of $42.5 million, or $0.65 per share, for the first six months of 2018.

Fiscal Year 2019 Revenue Guidance:

The Company is updating its fiscal year 2019 revenue expectations. For the twelve months ending December 31, 2019, the Company expects:

  • Net revenue of between $250 million and $262 million, representing growth of approximately 29% to 35% year-over-year, as compared to net revenue of $193.4 million for the twelve months ended December 31, 2018.  The Company’s prior guidance range for net revenue was $249 million to $262 million, representing growth of 29% to 35% year-over-year.
     
  • The updated 2019 net revenue guidance range assumes:
    • Net revenue from Advanced Wound Care products of between $219 million and $224 million, representing growth of approximately 33% to 36% year-over-year as compared to net revenue of $164.3 million for the twelve months ended December 31, 2018.
    • Net revenue from Surgical & Sports Medicine products of between $31 million and $38 million, representing growth of approximately 6% to 31% year-over-year as compared to net revenue of $29.1 million for the twelve months ended December 31, 2018.
    • The 2019 net revenue guidance range also assumes that net revenue from the sale of PuraPly products will represent between $110 million and $120 million of net revenue, representing growth of approximately 58% to 72% year-over-year, as compared to net revenue of $69.8 million for the twelve months ended December 31, 2018.

Conference Call:

Management will host a conference call at 8:00 a.m. Eastern Time on August 9th discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 6645209. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 6645209. The webcast will be archived at investors.organogenesis.com.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements relate to expectations or forecasts of future events.  Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue for fiscal 2019 and the breakdown of such revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories as well as the estimated revenue contribution of its PuraPly products. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements.  These factors include, but are not limited to: (1) the Company has incurred significant losses since inception and anticipates that it will incur substantial losses for the foreseeable future; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the impact of any changes to the reimbursement levels for the Company’s products and the impact to the Company of the loss of preferred “pass through” status for PuraPly AM and PuraPly on October 1, 2020; (7) the Company’s ability to maintain compliance with applicable Nasdaq listing standards; (8) changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (10) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2018. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.


ORGANOGENESIS HOLDINGS INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

      June 30,   December 31,
        2019       2018  
Assets        
Current assets:      
  Cash $ 20,040     $ 21,291  
  Restricted cash   119       114  
  Accounts receivable, net   34,157       34,077  
  Inventory   18,717       13,321  
  Prepaid expenses and other current assets   3,113       2,328  
    Total current assets   76,146       71,131  
Property and equipment, net   40,751       39,623  
Notes receivable from related parties   516       477  
Intangible assets, net   23,844       26,091  
Goodwill   25,539       25,539  
Deferred tax asset   238       238  
Other assets   1,040       579  
    Total assets $ 168,074     $ 163,678  
Liabilities and Stockholders’ Equity       
Current liabilities:      
  Deferred acquisition consideration $ 5,000     $ 5,000  
  Redeemable common stock liability   -       6,762  
  Current portion of notes payable   -       2,545  
  Current portion of capital lease obligations   2,442       2,236  
  Accounts payable   22,278       19,165  
  Accrued expenses and other current liabilities   20,679       20,388  
    Total current liabilities   50,399       56,096  
Line of credit   33,484       26,484  
Notes payable, net of current portion   -       12,578  
Term loan     39,662       -  
Deferred rent   456       130  
Capital lease obligations, net of current portion   14,655       15,418  
Other liabilities   6,220       5,931  
    Total liabilities   144,876       116,637  
Commitments and contingencies (Note 13)      
Stockholders’ equity:      
  Common stock, $0.0001 par value; 400,000,000 shares authorized; 92,071,270 and 91,261,413 shares issued;  91,342,722 and 91,261,413 shares outstanding at June 30, 2019 and December 31, 2018, respectively.   9       9  
  Additional paid-in capital   178,412       177,272  
  Accumulated deficit   (155,223 )     (130,240 )
    Total stockholders’ equity   23,198       47,041  
    Total liabilities and stockholders’ equity $ 168,074     $ 163,678  
           

 

ORGANOGENESIS HOLDINGS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

      Three Months Ended June 30,   Six Months Ended June 30,
        2019       2018       2019       2018  
Net revenue $ 64,948     $ 43,552     $ 122,071     $ 79,081  
Cost of goods sold   19,446       17,300       36,426       31,821  
Gross profit   45,502       26,252       85,645       47,260  
Operating expenses:              
  Selling, general and administrative   48,957       37,735       97,850       75,900  
  Research and development   3,864       2,048       7,235       4,872  
  Write-off of deferred offering costs   -       3,494       -       3,494  
    Total operating expenses   52,821       43,277       105,085       84,266  
Loss from operations   (7,319 )     (17,025 )     (19,440 )     (37,006 )
Other income (expense), net:              
  Interest expense, net   (2,187 )     (2,781 )     (3,965 )     (5,191 )
  Change in fair value of warrants   -       (175 )     -       (249 )
  Loss on the extinguishment of debt   -       -       (1,862 )     -  
  Other income (expense), net   (120 )     (2 )     12       3  
    Total other income (expense), net   (2,307 )     (2,958 )     (5,815 )     (5,437 )
Net loss before income taxes   (9,626 )     (19,983 )     (25,255 )     (42,443 )
Income tax expense   (23 )     (27 )     (60 )     (55 )
Net loss $ (9,649 )   $ (20,010 )   $ (25,315 )   $ (42,498 )
Net loss per share—basic and diluted $ (0.11 )   $ (0.30 )   $ (0.28 )   $ (0.65 )
Weighted average common shares outstanding—basic and diluted   90,647,352       66,361,998       90,625,850       65,347,076  
                   

 

ORGANOGENESIS HOLDINGS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

      Six Months Ended June 30,
        2019       2018  
Cash flows from operating activities:      
Net loss $ (25,315 )   $ (42,498 )
Adjustments to reconcile net loss to net cash used in operating activities:      
  Depreciation   1,761       1,747  
  Amortization of intangible assets   2,997       1,834  
  Non-cash interest expense   154       345  
  Deferred interest expense   536       111  
  Deferred rent expense   326       28  
  Write-off of deferred offering costs   -       3,494  
  Provision (benefit) recorded for sales returns and doubtful accounts   27       (307 )
  Provision recorded for inventory reserve   523       1,833  
  Stock-based compensation   458       568  
  Change in fair value of warrant liability   -       249  
  Loss on extinguishment of debt   1,862       -  
  Changes in fair value of forfeiture rights   -       589  
  Changes in operating assets and liabilities:      
    Accounts receivable   723       5,342  
    Inventory   (6,087 )     (1,648 )
    Prepaid expenses and other current assets   (785 )     (1,857 )
    Accounts payable   1,473       7,217  
    Accrued expenses and other current liabilities   122       524  
    Accrued interest—affiliate debt   -       1,777  
    Other liabilities   (449 )     414  
  Net cash used in operating activities   (21,674 )     (20,238 )
Cash flows from investing activities:      
Purchases of property and equipment   (1,251 )     (557 )
Acquisition of intangible asset   (250 )     -  
  Net cash used in investing activities   (1,501 )     (557 )
Cash flows from financing activities:      
Line of credit borrowings   7,000       4,827  
Proceeds from term loan   40,000       -  
Proceeds from long - term debt - affiliates   -       10,000  
Proceeds from notes payable   -       5,000  
Repayment of notes payable   (17,585 )     (10 )
Proceeds from the exercise of stock options   54       78  
Proceeds from the exercise of common stock warrants   628       -  
Redemption of redeemable common stock placed into treasury   (6,762 )     -  
Principal repayments of capital lease obligations   (557 )     (17 )
Payment of debt issuance costs   (849 )     (131 )
  Net cash provided by financing activities   21,929       19,747  
Change in cash and restricted cash    (1,246 )     (1,048 )
Cash and restricted cash, beginning of period   21,405       2,358  
Cash and restricted cash, end of period $ 20,159     $ 1,310  
Supplemental disclosure of cash flow information:      
Cash paid for interest $ 3,890     $ 2,507  
Cash paid for income taxes $ 67     $ 62  
Supplemental disclosure of non-cash investing and financing activities:      
Debt issuance costs included in accounts payable $ 75     $ 25  
Purchases of property and equipment in accounts payable and accrued expenses $ 1,638     $ 529  
Amounts due related to acquisition of intangible assets included in accrued expenses and other liabilities $ 500     $ -  
           

Use of Non‑GAAP Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non‑GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA principally as a measure of our operating performance and believes Adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision‑making.

We define EBITDA as net income (loss) before depreciation and amortization, net interest expense and income taxes and we define Adjusted EBITDA as EBITDA, further adjusted for the impact of certain items that we do not consider indicative of our core operating performance. These items consist of non-cash equity compensation, mark to market adjustments on our warrant liabilities, change in our contingent asset and liabilities, write-off of deferred offering costs, Avista merger transaction costs and loss on the extinguishment of debt.  We have presented Adjusted EBITDA in this press release because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, we believe that the exclusion of certain items in calculating Adjusted EBITDA can produce a useful measure for period-to-period comparisons of our business.

Our Adjusted EBITDA is not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA rather than net income (loss), which is the most directly comparable GAAP equivalent. Some of these limitations are:

  • Adjusted EBITDA excludes stock-based compensation expense, as stock-based compensation expense has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy; 
  • Adjusted EBITDA excludes depreciation and amortization expense and, although these are non-cash expenses, the assets being depreciated may have to be replaced in the future; 
  • Adjusted EBITDA excludes net interest expense, or the cash requirements necessary to service interest, which reduces cash available to us; 
  • Adjusted EBITDA excludes the impact of the changes in the fair value of our warrant liability and our contingent consideration forfeiture asset; 
  • Adjusted EBITDA excludes the write-off of deferred offering costs in connection with an abandoned public offering, as well as merger transaction costs, consisting primarily of legal and professional fees;
  • Adjusted EBITDA excludes the loss on extinguishment of debt, which is a non-cash loss related to the write-off of unamortized debt issuance costs upon repayment of affiliate and third-party debt, and related prepayment penalties;
  • Adjusted EBITDA excludes income tax expense (benefit); and
  • Other companies, including companies in our industry, may calculate Adjusted EBITDA differently, which reduces its usefulness as a comparative measure.

Because of these limitations, we consider, and you should consider, Adjusted EBITDA together with other operating and financial performance measures presented in accordance with GAAP. A reconciliation of Net loss, the most directly comparable measure calculated in accordance with GAAP, to Adjusted EBITDA, has been included below.

  Three Months Ended June 30,    Six Months Ended June 30, 
    2019       2018       2019       2018  
  (in thousands)   (in thousands)
Net loss $   (9,649 )   $   (20,010 )   $   (25,315 )   $   (42,498 )
Interest expense, net     2,187         2,781         3,965         5,191  
Income tax expense      23         27         60         55  
Depreciation     859         875         1,761         1,747  
Amortization     1,499         917         2,997         1,834  
EBITDA     (5,081 )       (15,410 )       (16,532 )       (33,671 )
Stock-based compensation expense     234         251         458         568  
Change in contingent consideration forfeiture asset (1)     -          -          -          589  
Change in fair value of warrant liability (2)     -          175         -          249  
Loss on extinguishment of debt (3)     -          -          1,862         -   
Write-off of deferred offering costs (4)     -          3,494         -          3,494  
Adjusted EBITDA $   (4,847 )   $   (11,490 )   $   (14,212 )   $   (28,771 )
               
Investor Inquiries:
Westwicke PartnersMike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500

Press and Media Inquiries:
OrganogenesisAngelyn Lowealowe@organo.com
781-774-9364

Organogenesis_Logo_Corporate.jpg

Source: Organogenesis Holdings Inc.



Shareholder Tools